IDEXX Laboratories (IDXX)
(Delayed Data from NSDQ)
$476.27 USD
+2.99 (0.63%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $476.27 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value C Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$476.27 USD
+2.99 (0.63%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $476.27 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value C Growth D Momentum D VGM
Zacks News
Idexx (IDXX) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
Idexx (IDXX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Top Ranked Momentum Stocks to Buy for October 13th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, October 13th.
The Zacks Analyst Blog Highlights: Alibaba, UnitedHealth, Merck & Co., Chipotle Mexican Grill and IDEXX Laboratories
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Alibaba, UnitedHealth, Merck & Co., Chipotle Mexican Grill and IDEXX Laboratories
Is IDEXX Laboratories (IDXX) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (IDXX) Outperforming Other Medical Stocks This Year?
Top Analyst Reports for Alibaba, UnitedHealth & Merck
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Alibaba Group (BABA), UnitedHealth Group (UNH) and Merck (MRK).
Should John Hancock Multifactor Mid Cap ETF (JHMM) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for JHMM
Idexx (IDXX) Up 2.6% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Idexx (IDXX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Idexx (IDXX) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Idexx (IDXX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
IDEXX (IDXX) Earnings Beat Estimates in Q2, Margins Rise
by Zacks Equity Research
IDEXX Laboratories (IDXX) registered strong contribution from its CAG business despite the pandemic-led challenges.
Has IDEXX Laboratories (IDXX) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (IDXX) Outperforming Other Medical Stocks This Year?
Idexx Laboratories (IDXX) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Idexx (IDXX) delivered earnings and revenue surprises of 43.33% and 9.93%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Will Epidolex Drive GW Pharmaceuticals' (GWPH) Q2 Earnings?
by Zacks Equity Research
Amid the pandemic situation, GW Pharmaceuticals (GWPH), which controls its own manufacture and supply chain, is expected to have faced minimum supply-related disruption unlike others.
Illumina (ILMN) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Illumina (ILMN) is upbeat about its second-quarter sequencing consumable revenue growth.
Should You Buy IDEXX Laboratories (IDXX) Ahead of Earnings?
by Zacks Equity Research
IDEXX Laboratories (IDXX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
What's in the Cards for CVS Health (CVS) in Q2 Earnings?
by Zacks Equity Research
CVS Health's (CVS) consumer centric digital strategy becomes even more relevant in Q2 with people increasingly using technology while staying at home.
STAAR Surgical (STAA) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
STAAR Surgical's (STAA) ICL line of products is likely to have boosted Q2 performance amid the coronavirus pandemic.
STERIS (STE) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
STERIS (STE) registers declines in Healthcare Products with neutral performance in Life Science and AST in April, which is likely to have impacted Q1 earnings.
Zimmer Biomet (ZBH) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
Zimmer Biomet's (ZBH) Hips and Knees portfolios are expected to have contributed to second-quarter top line despite pandemic-led business disruptions.
Henry Schein (HSIC) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
Henry Schein's (HSIC) medical business' PPE sales are likely to have boosted Q2 performance amid the coronavirus pandemic.
What's in Store for IDEXX Laboratories (IDXX) in Q2 Earnings?
by Zacks Equity Research
IDEXX's (IDXX) top line is likely to have benefited from a robust CAG business and regulatory approvals for its COVID-19 tests.
Deferred Procedures to Mar Boston Scientific (BSX) Q2 Earnings
by Zacks Equity Research
With lockdowns continuing through all three months of the second quarter, Boston Scientific (BSX) is expected to have faced a more dreadful time.
Will Idexx (IDXX) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Idexx (IDXX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Are You Looking for a Top Momentum Pick? Why Idexx Laboratories (IDXX) is a Great Choice
by Zacks Equity Research
Does Idexx Laboratories (IDXX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Medical Instruments Outlook Dull Amid Coronavirus Crisis
by Urmimala Biswas
Many sub domains within the medical instrument space are bearing the brunt of the coronavirus-led prolonged stay-at-home orders.
IDEXX Gains on Diagnostics Revenues, New Coronavirus Tests
by Zacks Equity Research
IDEXX's (IDXX) human health business, OPTI Medical Systems' newly-developed PCR laboratory test kit named OPTI SARS-CoV-2 RNA RT-PCR gains market acceptance.